Immunocore Holdings plc Quarterly Income Tax Expense (Benefit) in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Immunocore Holdings plc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2023 to Q3 2024.
  • Immunocore Holdings plc Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was -$2.64M, a 1410% decline year-over-year.
  • Immunocore Holdings plc Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was -$6.71M.
  • Immunocore Holdings plc annual Income Tax Expense (Benefit) for 2023 was -$5.6M, a 148% decline from 2022.
  • Immunocore Holdings plc annual Income Tax Expense (Benefit) for 2022 was $11.7M, a 7673% increase from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$6.71M -$2.64M -$2.47M -1410% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$4.24M $1.49M +$1.3M +678% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$5.54M $357K +$64K +21.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$5.6M -$5.91M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$175K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $191K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $293K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.